Publication details

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021

Authors

ANGELA MC Rose NICOLAY Nathalie MARTIN Virginia Sandonis MAZAGATOS Clara PETROVIC Goranka NIESSEN F Annabel MACHADO Ausenda LAUNAY Odile DENAYER Sarah SEYLER Lucie BARUCH Joaquin BURGUI Cristina LOGHIN Isabela I DOMEGAN Lisa VAIKUTYTE Roberta HUSA Petr PANAGIOTAKOPOULOS George AOUALI Nassera DUERRWALD Ralf HOWARD Jennifer POZO Francisco SASTRE-PALOU Bartolome NONKOVIC Diana KNOL Mirjam J KISLAYA Irina NGUYEN Liem Binh Luong BOSSUYT Nathalie DEMUYSER Thomas DZIUGYTE Ausra MARTINEZ-BAZ Ivan POPESCU Corneliu DUFFY Roisin KULIESE Monika SOUČKOVÁ Lenka MICHELAKI Stella SIMON Marc REICHE Janine OTERO-BARROS Maria Teresa MAKARIC Zvjezdana Lovric BRUIJNING-VERHAGEN Patricia C J L GOMEZ Veronica LESIEUR Zineb BARBEZANGE Cyril ELS Van Nedervelde BORG Maria-Louise CASTILLA Jesus LAZAR Mihaela DONNELL Joan JONIKAITE Indre DEMLOVÁ Regina AMERALI Marina WIRTZ Gil TOLKSDORF Kristin VALENCIANO Marta BACCI Sabrina KISSLING Esther

Year of publication 2023
Type Article in Periodical
Magazine / Source EUROSURVEILLANCE
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2023.28.47.2300186
Doi http://dx.doi.org/10.2807/1560-7917.ES.2023.28.47.2300186
Keywords Alpha; Delta; Europe; hospital; SARS-CoV-2; vaccine effectiveness
Description IntroductionTwo large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients >= 20 years, combining data from these networks during Alpha (March-June)- and Delta (June-December)-dominant periods, 2021.MethodsForty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case-control design. We defined complete primary series vaccination (PSV) as two doses of a two-dose or one of a single-dose vaccine >= 14 days before onset.ResultsWe included 1,087 cases (538 controls) and 1,669 cases (1,442 controls) in the Alpha- and Delta-dominant periods, respectively. During the Alpha period, VE against hospitalisation with SARS-CoV2 for complete Comirnaty PSV was 85% (95% CI: 69-92) overall and 75% (95% CI: 42-90) in those aged >= 80 years. During the Delta period, among SARI patients >= 20 years with symptom onset >= 150 days from last PSV dose, VE for complete Comirnaty PSV was 54% (95% CI: 18-74). Among those receiving Comirnaty PSV and mRNA booster (any product) >= 150 days after last PSV dose, VE was 91% (95% CI: 57-98). In time-since-vaccination analysis, complete all-product PSV VE was > 90% in those with their last dose < 90 days before onset; >= 70% in those 90-179 days before onset.ConclusionsOur results from this EU multi-country hospital setting showed that VE for complete PSV alone was higher in the Alpha- than the Delta-dominant period, and addition of a first booster dose during the latter period increased VE to over 90%.

You are running an old browser version. We recommend updating your browser to its latest version.

More info